Events

Precision Medicine Research Conference Thursday, October 30, 2025 11AM-12PM Belfer Research Building, Room 1401 and via Zoom “Clinical Tumor Sequencing Cases” Presented by Neal Lindeman, MD Faculty Distinguished Professor of Pathology & Vice Chair, Laboratory Medicine and Molecular Pathology Weill Cornell Medicine Presented by James Solomon, PhD, MD Assistant Professor of Pathology and Laboratory Medicine Weill Cornell Medicine Presented by: Selda Karaaslan, MD, PhD Fellow in Pathology and Laboratory Medicine, NewYork-Presbyterian * This activity has been approved for AMA PRA Category 1 Credit(s)™*

Englander Institute for Precision Medicine Seminar Series “AI Agents for Clinical Research” Presented by Jimeng Sun, PhD Health Innovation Professor, Siebel School of Computing & Data Science, Carle Illinois College of Medicine, University of Illinois Urbana-Champaign Thursday, October 30, 2025 12:00 PM – 1:00 PM EDT Abstract: Clinical research is slowed by inefficiencies in literature review, data wrangling, protocol drafting, and regulatory documentation—leading to costly delays in over 80% of trials. This talk introduces TrialMind, a generative AI platform designed to serve as an end-to-end assistant for the clinical trial lifecycle. TrialMind combines specialized AI agents for systematic literature review, data science, trial design optimization, patient recruitment (TrialGPT), site selection (FRAMM), and outcome prediction. Drawing from large-scale benchmarks such as TrialPanorama and BioDSA-1K, the platform integrates domain knowledge, verifiable grounding, and regulatory alignment to deliver both accuracy and compliance. We will present key findings from our recent publications in Nature Communications, NPJ Digital Medicine, and Cell Patterns, highlighting advances in eligibility criteria generation, informed consent form drafting, and patient-trial matching. Finally, we will discuss the vision of AI-native clinical trials—where human expertise is augmented by trustworthy AI agents to accelerate discovery, reduce cost, and improve equity in trial participation.